Kancera Ab Stock Fundamentals
| KAN Stock | SEK 1.32 0.08 6.45% |
Kancera AB fundamentals help investors to digest information that contributes to Kancera AB's financial success or failures. It also enables traders to predict the movement of Kancera Stock. The fundamental analysis module provides a way to measure Kancera AB's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kancera AB stock.
Kancera |
Kancera AB Company Return On Asset Analysis
Kancera AB's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Kancera AB Return On Asset | -0.27 |
Most of Kancera AB's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kancera AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Kancera AB has a Return On Asset of -0.2736. This is 96.87% lower than that of the Healthcare sector and 98.84% lower than that of the Biotechnology industry. The return on asset for all Sweden stocks is 95.43% higher than that of the company.
Kancera AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Kancera AB's current stock value. Our valuation model uses many indicators to compare Kancera AB value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kancera AB competition to find correlations between indicators driving Kancera AB's intrinsic value. More Info.Kancera AB is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kancera AB's earnings, one of the primary drivers of an investment's value.Kancera Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kancera AB's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kancera AB could also be used in its relative valuation, which is a method of valuing Kancera AB by comparing valuation metrics of similar companies.Kancera AB is currently under evaluation in return on asset category among its peers.
Kancera Fundamentals
| Return On Equity | -0.47 | |||
| Return On Asset | -0.27 | |||
| Operating Margin | (72.39) % | |||
| Current Valuation | 14.76 M | |||
| Shares Outstanding | 79.53 M | |||
| Shares Owned By Insiders | 13.72 % | |||
| Shares Owned By Institutions | 2.86 % | |||
| Price To Earning | (11.64) X | |||
| Price To Book | 1.44 X | |||
| Price To Sales | 168.19 X | |||
| Revenue | 1.7 M | |||
| Gross Profit | 1.7 M | |||
| EBITDA | (45.35 M) | |||
| Net Income | (45.69 M) | |||
| Cash And Equivalents | 106.52 M | |||
| Cash Per Share | 0.08 X | |||
| Total Debt | 442 K | |||
| Debt To Equity | 33.30 % | |||
| Current Ratio | 2.11 X | |||
| Book Value Per Share | 1.50 X | |||
| Cash Flow From Operations | (44.12 M) | |||
| Earnings Per Share | (0.87) X | |||
| Target Price | 1.6 | |||
| Beta | 1.28 | |||
| Market Capitalization | 262.69 M | |||
| Total Asset | 133.64 M | |||
| Working Capital | 11 M | |||
| Current Asset | 16 M | |||
| Current Liabilities | 5 M | |||
| Net Asset | 133.64 M |
About Kancera AB Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kancera AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kancera AB using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kancera AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Kancera AB , a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. The company was founded in 2010 and is based in Solna, Sweden. Kancera AB operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Kancera Stock Analysis
When running Kancera AB's price analysis, check to measure Kancera AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kancera AB is operating at the current time. Most of Kancera AB's value examination focuses on studying past and present price action to predict the probability of Kancera AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kancera AB's price. Additionally, you may evaluate how the addition of Kancera AB to your portfolios can decrease your overall portfolio volatility.